Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

NCRI 2021 | FOCUS4-N: Maintenance capecitabine monotherapy in mCRC

Jenny Seligmann, MBChB, PhD, University of Leeds, Leeds, UK, describes the results from the FOCUS4-N trial (EudraCT Number: 2012-005111-12) investigating oral maintenance capecitabine in patients with metastatic colorectal cancer as opposed to capecitabine and bevacizumab, the standard of care, in colorectal cancer. Patients in the FOCUS4-N trial either received capecitabine monotherapy or a treatment break as defined in the COIN trial (NCT00182715). The primary endpoint of progression-free survival (PFS) was met in patients receiving capecitabine. Dr Seligmann additionally discusses whether PFS or overall survival (OS) is the superior primary endpoint in maintenance trials. This interview took place at the National Cancer Research Institute (NCRI) Festival 2021.

Disclosures

Dr Seligmann has received honoraria/travel/consultancy fees from Servier, Merck Serono, Pierre Fabre, Roche Diagnostics, BMS, and GI Connect.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.